AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s ...
AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotechnology company headquartered in San Diego, California. Founded in 2005, the company is dedicated to discovering and developing innovative immunology therapeutics for patients with autoimmune and inflammatory diseases. AnaptysBio leverages its proprietary antibody discovery platform to generate a robust pipeline of product candidates. ...AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotechnology company headquartered in San Diego, California. Founded in 2005, the company is dedicated to discovering and developing innovative immunology therapeutics for patients with autoimmune and inflammatory diseases. AnaptysBio leverages its proprietary antibody discovery platform to generate a robust pipeline of product candidates. Key programs include rosnilimab, a selective pathogenic T cell depleter that recently completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody in Phase 1a targeting plasmacytoid dendritic cells; and imsidolimab, an anti-IL-36 receptor antibody in Phase 3 for generalized pustular psoriasis. The company also has a partnered program, dostarlimab (PD-1 antagonist), for solid tumor indications. AnaptysBio has strategic collaborations with GSK, which includes royalties and milestones on Jemperli (dostarlimab), and with Vanda Pharmaceuticals for imsidolimab. The company manages these financial collaborations to generate revenue and maximize shareholder value. Financially, AnaptysBio reported a market capitalization of approximately $1.68 billion, with a price-to-sales ratio of 7.21 and an enterprise value of $1.71 billion. The company has cash reserves of around $9.98 per share and a current ratio of 7.58, indicating strong liquidity. However, it has a negative net profit margin of -11.5% and a return on equity of 4.43, reflecting its ongoing investment in R&D, which accounts for 55.4% of revenue. With 104 full-time employees, the company is led by CEO Daniel Faga, who has served since March 2022. AnaptysBio was incorporated in 2005, went public in January 2017, and continues to advance its pipeline with the goal of bringing novel treatments to patients. Its long-term vision emphasizes both clinical innovation and prudent management of partnerships to ensure sustainable growth.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$234.6M
+157.0%
-76.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-13.2M
+90.9%
-206.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+99.0%
+224.5%
-51.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+20.4%
+116.2%
-319.3%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-5.6%
+96.5%
-551.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$19.6M
+114.5%
-126.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+8.4%
+105.6%
-212.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
37.9%
-92.7%
+178.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
9.07x
-4.6%
-16.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
